EP1013 is a broad-spectrum selective inhibitor of Caspase used in the study of type 1 diabetes.

EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function.EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal rate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups.

223568-55-6

C18H23FN2O6

382.38

F1013;EP1013

DMSO:60 mg/mL (156.91 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years